Journal of Alzheimer's Disease Reports · Nov 10, 2026
Four-axis fecal metabolome alterations and an exploratory 5-metabolite signature for detecting subjective cognitive decline across the clinically defined Alzheimer's disease spectrum
By Feng Y, Wu R, Chen Y et al.
Background: The gut-brain axis is implicated in Alzheimer's disease (AD), but fecal metabolomic changes across the healthy controls (HC)→subjective cognitive decline (SCD)→mild cognitive impairment (MCI)→AD clinical spectrum, especially at the SCD stage, remain poorly characterized. Without amyloid/tau confirmation, our groups represent clinically defined cognitive stages rather than confirmed AD. Objective: To profile the fecal metabolome across four clinically defined groups and test whether a metabolite signature distinguishes SCD from HC. Methods: Untargeted LC-MS was performed on 84 fecal samples (10 HC, 22 SCD, 23 MCI, 29 AD). After excluding contaminants, 1966 B(i)-level metabolites entered analysis. Spearman trend tests (age- and sex-adjusted, BH-FDR<0.05) and nested cross-validated Random Forest classification were applied, with an age-restricted 60–80 subset (n = 60) for sensitivity analysis. Results: 374 metabolites (19.0%) showed a monotonic cross-sectional gradient, clustering on four axes: bile acid biosynthesis, purine metabolism, neurotransmitter processing, and vitamins. Cortisol was reduced at SCD (p = 2.3 × 10 ⁻⁴ ), attenuating to p = 1.7 × 10 ⁻³ after age restriction. A nested cross-validation metabolite feature-selection and classification pipeline (metabolites + age + sex, excluding Mini-Mental State Examination) achieved LOO-CV AUC=0.959 (95% CI: 0.883–1.000) for SCD versus HC; a representative five-metabolite signature is reported for descriptive purposes only. Conclusions: Fecal metabolomic differences are detectable at the SCD stage in this cross-sectional cohort. These findings are hypothesis-generating and require external validation in larger, age-matched cohorts with amyloid/tau confirmation.